Tasman Medical Journal

ISSN: 2652-1881

Clinical and animal evidence for efficacy of molnupiravir in the treatment of infection with COVID-19

J. Alasdair Millar

Full Text

The media has widely and rightly reported the effectiveness of a new orally-active antiviral drug named molnupiravir (MK-4482, EIDD-2801) against SARS-CoV-2 (COVID-19).  The clinical evidence has been sufficiently strong to prompt the suspension of a phase III randomised trial (the MOVe-OUT trial), and the manufacturers (MSD and Ridgeback Biotherapeutics) are making an application for Emergency Use Authorisation to the US Food and Drug Administration.  Recognising the potential of the drug, the Australian government has purchased 300,000 doses.  This brief report of the evidence is presented for the benefit of TMJ readers.

The MOVe-OUT trial was in at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19.  In the light of these results, recruitment to the study has been stopped after enrolment of approximately 1400 patients, so a further analysis will doubtless appear in due course.  We note that the reference below is a sponsor publication and that the trial does not appear to have been published in a peer-reviewed journal.  In the present report several explicit risks and uncertainties are acknowledged, including the possibility that future results will not support this interim analysis.

The manufacturer’s report1 presents the results shown in the table.

Number and proportion of COVID-19 infected patients needing to be admitted to hospital after treatment with either molnupiravir or placebo in the MOVe-OUT Clinical Trial, and the number of deaths with each treatment up to 29 days. Differences are statistically significant.

These are highly encouraging results, giving strong clinical support to detailed positive results in mice with transplanted COVID-infected human lung tissue.2  In that work, Dr Angela Wahl and colleagues at the University of North Carolina at Chapel Hill, NC, USA describe the effect of giving molnupiravir (EIDD-2801) to the mice to come to a detailed understanding of the pathogenesis of the coronavirus infection (including SARS-Cov-2 infection) and the efficacy of the drug in treating COVID-19 infection in that model.  They observed expression of viral genes peaking 2 days after infection, and stimulation of native genes also.  Molnupiravir or placebo was administered to the mice either 2 days after infection, whence viral titres were reduced by 95%, or 12 hours before and 12-hourly thereafter, with a 100,000-fold reduction in viral titres.  In contrast, animals not given molnupiravir displayed marked lung destruction when inoculated.  These results can be seen graphically in Fig. 4 of the paper.2

These human and animal results show dramatically the efficacy of molnupiravir against SARS-CoV-2 infection.

As a point of interest relating to the controversy over the emergence of SARS-CoV-2, the Chapel Hill investigators found in the course of their work evidence consistent with direct human COVID-19 infection from bats.

REFERENCES

  1. MSD and Risgeback Company Announcement. Interim analysis, MOVe-OUT Trial. https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/. Accessed 4/10/21
  2. Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 2021: 591; 451-457. https://doi.org/10.1038/s41586-021-03312-w

Publication Categories

AUTHOR INFORMATION

Clin Prof J. Alasdair Millar

OCCUPATION
Editor
INSTITUTIONAL AFFILIATIONS
Tasman Medical Journal

Test Pop-up